ABO2102

KRAS neoantigen mRNA vaccine

Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for ABO2102, covering 2025-05-21 to 2026-04-06. Get the full timeline:

Most recent: Clinical Trial Update: Study of ABO2102 in KRAS-Mutated Solid Tumors [Phase 1]